Core E: Cellular and Organismic Systems for Antiviral Testing

用于抗病毒测试的核心E细胞和组织系统 摘要 蜂窝和组织系统核心通过协调和 实施细胞和动物抗病毒测试实验，以满足每个项目的目标。 该AViDD中心需要一个细胞和组织系统核心小组，因为需要 在确定每种化合物的抗病毒活性方面的一致性，以及由于对 处理需要高度控制的病原体。在明尼苏达大学、波士顿大学和 爱荷华大学，细胞和组织系统核心提供专门的资源和 执行细胞和动物BSL2、BSL3、BSL4研究的管理框架。Core E将专注于 SARS-CoV-2、寨卡病毒、埃博拉病毒和拉萨病毒。此核心将通过HIGH评估验证的命中 在目标1中进行吞吐量筛选。成功的化合物将返回项目和岩心进行进一步筛选 精致。然后，AIM 2将评估精制化合物的抗病毒活性和剂量反应，潜在的 逃逸，并在原代人类细胞中发挥效力。最后，在目标2中证明有效的化合物将是 在目标3的相关动物疾病模型中评价预防和治疗效果。

Core E – Cellular and Organismic Systems for Antiviral Testing Summary The Cellular and Organismic Systems Core supports the entire Midwest AViDD Center by coordinating and implementing cell and animal antiviral testing experiments required to address the aims in each of the Projects. A Cellular and Organismic Systems Core group is necessary for this AViDD Center because of the need for consistency in determining the antiviral activity of each compound, and because of the intense requirements for handling pathogens that require high containment. Based at the University of Minnesota, Boston University and the University of Iowa, the Cellular and Organismic Systems Core provides the specialized resources and administrative framework for performing cellular and animal BSL2, BSL3, BSL4 studies. Core E will focus on SARS-CoV-2, Zika virus, Ebola virus and Lassa virus. This core will evaluate validated hits through high throughput screening in Aim 1. Successful compounds will then go back to the projects and cores for further refinement. Aim 2 will then evaluate refined compounds for antiviral activity and dose response, the potential for escape, and efficacy in primary human cells. Finally, compounds that demonstrate efficacy in Aim 2 will be evaluated for prophylactic and therapeutic efficacy in relevant animal disease models in Aim 3.